List view / Grid view
3 September 2014 | By The University of Nottingham
New research from The University of Nottingham looks set to improve screening for new cancer drugs and drug delivery systems specifically designed for children with brain tumours...
3 September 2014 | By kdm communications
Cresset is pleased to announce that Selvita S.A., a drug discovery company located in Krakow, Poland, has licensed Cresset’s Forge and Spark...
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
3 September 2014 | By European Medicines Agency
The European Medicines Agency is pleased to announce two new appointments to its management team...
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...
3 September 2014 | By Amgen
First Marketing Authorization Application for an oncolytic immunotherapy in the European Union...
3 September 2014 | By Andrew Lloyd & Associates
CleveXel Pharma announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products...
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
2 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe...
2 September 2014 | By Daiichi Sankyo
A SGLT2 inhibitor for Type2 Diabetes Mellitus...
2 September 2014 | By Roche
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays...
